Epigenetic Therapeutic Targets Summit

The Epigenetic Therapeutic Targets Summit is focused on Identify, Validate & Translate Epigenetic-Targeted Therapies into Clinical Success.

The Epigenetic Therapeutic Targets Summit covers topics such as:

• Early evidence of antitumor activity that was observed with CC-90011 in some NENs and NHLs with Bristol-Myers Squibb
• Targeting cancer with first-in-class inhibitors of the KAT6 with Pfizer
• A novel CBP/p300 inhibitor which antagonizes AR signalling with Forma Therapeutics
• New potential for epigenetic drugs in fields other than cancer including treating parasite infection with University of Rome
• Targeting SMARCA4-mutant lung cancers through selective, chemically-induced degradation of SMARCA2 with Genentech
• Speeding up discovery with high throughput screening with University of California San Diego

The Epigenetic Therapeutic Targets Summit will be held on 13-15 Jul 2021.